Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity

Details for Australian Patent Application No. 2005250161 (hide)

Owner Solvay Pharmaceuticals B.V.

Inventors Kruse, Cornelis G.; Lange, Josephus H.m.; Wals, Henderik C.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2005250161

PCT Pub. Number WO2005/118553

Priority 60/574,939 28.05.04 US; 04076619.8 28.05.04 EP

Filing date 26 May 2005

Wipo publication date 15 December 2005

Acceptance publication date 7 October 2010

International Classifications

C07D 233/90 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

Event Publications

11 January 2007 PCT application entered the National Phase

  PCT publication WO2005/118553 Priority application(s): WO2005/118553

7 October 2010 Application Accepted

  Published as AU-B-2005250161

3 February 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005250163-Binding molecules capable of neutralizing rabies virus and uses thereof

2005250157-Mercaptoimidazoles as CCR2 receptor antagonists